Pathogenic autoantibody derived from Treg-deficient scurfy mice targets Col7 and leads to Epidermolysis bullosa acquisita-like blistering disease

2021 ◽  
Author(s):  
Elisabeth Vicari ◽  
Stefanie Haeberle ◽  
Vanessa Bolduan ◽  
Torben Ramcke ◽  
Artem Vorobyev ◽  
...  
Keyword(s):  
Epidermolysis Bullosa ◽  
Epidermolysis Bullosa Acquisita ◽  
Blistering Disease ◽  
Pathogenic Autoantibody

A rare occurrence of epidermolysis bullosa acquisita in a patient with retroviral disease

2017 ◽  
Vol 28 (12) ◽  
pp. 1255-1258
Author(s):  
Zambare Uddhao ◽  
Chhonkar Aditi ◽  
Nayak Chitra ◽  
Tambe Swagata
Keyword(s):  
Hiv Infection ◽  
Epidermolysis Bullosa ◽  
Epidermolysis Bullosa Acquisita ◽  
Rare Occurrence ◽  
Type Vii Collagen ◽  
Blistering Disease

Epidermolysis bullosa acquisita is a chronic subepidermal blistering disease associated with autoimmunity to type-VII collagen within anchoring fibrils located at the dermo-epidermal junction. This entity is rarely reported from India. It can have a variety of presentations. Its occurrence with retroviral disease has rarely been reported. Here, we present a case of epidermolysis bullosa acquisita in a patient with HIV infection.

Epidermolysis Bullosa Acquisita Responsive to Dapsone Therapy

2001 ◽  
Vol 5 (5) ◽  
pp. 397-399 ◽  
Author(s):  
Amy P. Hughes ◽  
Jeffrey P. Callen
Keyword(s):  
Epidermolysis Bullosa ◽  
Oral Prednisone ◽  
Epidermolysis Bullosa Acquisita ◽  
Effective Agent ◽  
Complete Control ◽  
Bullous Eruption ◽  
Immunofluorescence Studies ◽  
History Of ◽  
Blistering Disease ◽  
One Year

Background: Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is frequently resistant to therapy. Objective: A 58-year-old man who had a one-year history of a bullous eruption involving the hands, forearms, trunk, scalp, and oral mucosa. Histopathology revealed a subepidermal bulla, and direct and indirect immunofluorescence studies were consistent with EBA. The patient failed respond to niacinamide and tetracycline and oral prednisone 40 mg per day. Methods: Complete control of his blistering was achieved within two months of initiating oral dapsone, 150 mg per day. Conclusion: Dapsone may be an effective agent for some patients with EBA.

Serial Measurement of Anti-type VII Collagen Antibodyis Useful in Treatment of Epidermolysis Bullosa Acquisita

2013 ◽  
Vol 75 (5) ◽  
pp. 409-414 ◽  
Author(s):  
Haruna SAWAKI ◽  
Amiko HAKUTA ◽  
Miwa KANAOKA ◽  
Kazuko NAKAMURA ◽  
Takashi HASHIMOTO ◽  
...  
Keyword(s):  
Epidermolysis Bullosa ◽  
Epidermolysis Bullosa Acquisita ◽  
Serial Measurement ◽  
Type Vii Collagen
Sign in / Sign up

Export Citation Format

Share Document